Analysts and calls -- US Bancorp Piper Jaffray Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Analysts and calls -- US Bancorp Piper Jaffray

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (12)	6/27/2003 4:43:21 PM
From: Icebrg	Read Replies (1) of 22

Trimeris initiated with "outperform" - update Updated Friday, June 27, 2003 2:15:39 PM ET US Bancorp Piper Jaffray NEW YORK, June 27 (New Ratings) — Analyst Thomas Wei of US Bancorp Piper Jaffray initiates coverage of Trimeris Inc (TRMS) with an "outperform" rating. The target price is set to $59. In a research note published this afternoon, the analyst mentions that Trimeris' HIV drug, Fuzeon, has experienced an accelerated demand upsurge over the recent months. US Bancorp Piper Jaffray expects the drug's demand to continuously outpace its supply levels over the long-term. [The stock opened the day at 46.58 and closed 19 cents higher].

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next